CD19 is a protein on B cells from the start until they mature. It’s always there, even on cancerous B cells. This makes CD19 ...

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic (B ...

Researchers from the Josep Carreras Leukaemia Research Institute have found that the efficacy of varni-cel, a CAR-T infusion ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

CAR T cell therapy has demonstrated efficacy in treating B-cell malignancies, achieving high response rates and durable remissions. However, translating this success to acute myeloid leukemia (AML ...

Discover how next-generation "switchable" CAR-T cells could improve both the safety and efficacy of CAR-T therapies.

The T-cell malignancies market is driven by the rising incidence of these cancers, advancements in treatment options, and strategic partnerships within the biopharma industry. Increasing ...

CAR-T cell therapy involves some known side-effects called Cytokine Release Syndrome (CRS), Macrophage Activation Syndrome ...

In a pioneering move, MGM Medical College in Indore has launched CAR T cell therapy for blood cancer treatment, making it ...

Apollo Cancer Centers, Visakhapatnam on Tuesday said it has introduced CAR-T cell therapy for the first time in the state of ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing malignant B cells PHILADELPHIA, Oct.